ReviewWorld journal of diabetes2023
Gut microbiome supplementation as therapy for metabolic syndrome.
Review in World journal of diabetes, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 26 citations in OpenAlex.
- Short-chain fatty acids and type 2 diabetes: a bibliometric analysis of knowledge structure, research hotspots, and future directions.Frontiers in microbiology · 2025Pooled it
- Trial
- Trial
- The Oral Microbiome, Oral Hyperpermeability, and Periodontitis in Metabolic Syndrome.Advances in experimental medicine and biology · 2026Review
- The Role of the Gut Microbiome in Type 2 Diabetes Mellitus.International journal of molecular sciences · 2025Review
- Probiotics and Food Bioactives: Unraveling Their Impact on Gut Microbiome, Inflammation, and Metabolic Health.Probiotics and antimicrobial proteins · 2025Review
- The Gut Microbiota-anxiety Connection: Evidence, Mechanisms, and Therapeutic Strategies.Current medicinal chemistry · 2025Review
- New therapy for metabolic syndrome: Gut microbiome supplementation.World journal of diabetes · 2024Article
- Harnessing the Power of the Gut Microbiome: A Review of Supplementation Therapies for Metabolic Syndrome.Cureus · 2024Review
- Metabolic Syndrome and Psoriasis: Pivotal Roles of Chronic Inflammation and Gut Microbiota.International journal of molecular sciences · 2024Review
- Okinawa-Based Nordic Diet Decreases Plasma Levels of IAPP and IgA against IAPP Oligomers in Type 2 Diabetes Patients.International journal of molecular sciences · 2024Article
- Modulating the Gut Microbiota and Metabolites with Traditional Chinese Medicines: An Emerging Therapy for Type 2 Diabetes Mellitus and Its Complications.Molecules (Basel, Switzerland) · 2024Review
- Metabolic syndrome's new therapy: Supplement the gut microbiome.World journal of diabetes · 2024Article
- Review
- Harnessing Microbiome Therapy to Treat Metabolic Syndrome.AACE endocrinology and diabetesReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The gut microbiome is defined as an ecological community of commensal symbiotic and pathogenic microorganisms that exist in our body. Gut microbiome dysbiosis is a condition of dysregulated and disrupted intestinal bacterial homeostasis, and recent evidence has shown that dysbiosis is related to chronic inflammation, insulin resistance, cardiovascular diseases (CVD), type 2 diabetes mellitus (T2DM), and obesity. It is well known that obesity, T2DM and CVD are caused or worsened by multiple factors like genetic predisposition, environmental factors, unhealthy high calorie diets, and sedentary lifestyle. However, recent evidence from human and mouse models suggest that the gut microbiome is also an active player in the modulation of metabolic syndrome, a set of risk factors including obesity, hyperglycemia, and dyslipidemia that increase the risk for CVD, T2DM, and other diseases. Current research aims to identify treatments to increase the number of beneficial microbiota in the gut microbiome in order to modulate metabolic syndrome by reducing chronic inflammation and insulin resistance. There is increasing interest in supplements, classified as prebiotics, probiotics, synbiotics, or postbiotics, and their effect on the gut microbiome and metabolic syndrome. In this review article, we have summarized current research on these supplements that are available to improve the abundance of beneficial gut microbiota and to reduce the harmful ones in patients with metabolic syndrome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.